Abiopharma

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve QUINIDINE SULFATE

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve NALOXONE HYDROCHLORIDE

FDA approve MEROPENEM

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve CEFAZOLIN SODIUM

FDA approve FENOFIBRATE

FDA approve MEROPENEM

FDA approve HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

Xylo Technologies Ltd (XYLO) was removed from the list of traded instruments on NASDAQ exchange

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Xylo Technologies Ltd. - American Depositary Shares.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Xylo Technologies Ltd. - American Depositary Shares.